Accuray (ARAY) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Share on StockTwits

Accuray (NASDAQ:ARAY) posted its quarterly earnings data on Tuesday. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02), MarketWatch Earnings reports. The company had revenue of $95.83 million for the quarter, compared to analyst estimates of $95.10 million. Accuray had a negative net margin of 5.90% and a negative return on equity of 43.31%. During the same quarter last year, the company earned ($0.11) EPS.

Shares of ARAY traded up $1.21 during midday trading on Wednesday, reaching $4.65. The company had a trading volume of 168,386 shares, compared to its average volume of 970,195. Accuray has a 1-year low of $3.20 and a 1-year high of $6.15. The company has a market capitalization of $290.63 million, a PE ratio of -16.57 and a beta of 1.70. The company has a quick ratio of 1.04, a current ratio of 1.68 and a debt-to-equity ratio of 2.70.

In other news, CFO Shigeyuki Hamamatsu sold 8,762 shares of the stock in a transaction on Tuesday, October 2nd. The stock was sold at an average price of $4.48, for a total transaction of $39,253.76. Following the completion of the transaction, the chief financial officer now directly owns 116,238 shares in the company, valued at approximately $520,746.24. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Joshua Levine sold 17,242 shares of the stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $4.38, for a total value of $75,519.96. Following the transaction, the chief executive officer now owns 1,387,162 shares of the company’s stock, valued at $6,075,769.56. The disclosure for this sale can be found here. Insiders sold a total of 27,790 shares of company stock valued at $122,775 over the last ninety days. Corporate insiders own 3.40% of the company’s stock.

A number of equities research analysts recently commented on the company. BidaskClub lowered Accuray from a “sell” rating to a “strong sell” rating in a research report on Friday, August 17th. Citigroup reduced their target price on Accuray from $4.00 to $3.50 and set a “sell” rating for the company in a research note on Friday, August 17th. BTIG Research reaffirmed a “hold” rating on shares of Accuray in a research note on Wednesday, August 22nd. Zacks Investment Research raised Accuray from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 3rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $6.00 target price on shares of Accuray in a research note on Friday, August 17th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $6.29.

About Accuray

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Featured Story: How can you know how many shares are floating?

Earnings History for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply